Epoetin alfa improves survival after chemoradiation for Stage III esophageal cancer: Final results of a prospective observational study

Conclusions: The findings suggest that epoetin alfa when used to maintain the hemoglobin levels at 12 to 14 g/dL can improve OS and LC of Stage III esophageal cancer patients.